Flavopiridol

(alvocidib)

Phase 3Small molecule

Alvocidib is being investigated as a cancer treatment, particularly for certain blood cancers like chronic lymphocytic leukemia. It works by stopping cancer cells from dividing and growing.[1] Flavopiridol is currently being investigated across 20 indications[3], with its most advanced program in Phase 3.[1]

Flavopiridol is one of 550 small molecule programs targeting Kidney Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

549

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

Lymphoid NeoplasmActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Liver CancerActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Cutaneous MelanomaPhase 2

Active, not recruiting

Lymphoid NeoplasmPhase 1

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 1

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Flavopiridol

Sumitomo Pharma America, Inc.

Phase 3

2 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Prolia

Amgen

Preclinical

14 7

Gemzar

GGynecologic Oncology Group

Preclinical

22 8

Voltaren

Novartis

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors8 trials

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00006485

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00007917·58 enrolled

Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00016185

Show 5 more trials

Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00003690·48 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00046917·13 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00045448

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00324480·60 enrolled

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00080990·46 enrolled

Acute Myeloid Leukemia7 trials

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Completed·SSumitomo Pharma Co., Ltd.·Phase 1·NCT03563560·10 enrolled

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00634244·92 enrolled

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00407966·45 enrolled

Show 4 more trials

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01349972·172 enrolled

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00795002·78 enrolled

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT03298984·32 enrolled

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Completed· AbbVie logo

AbbVie·Phase 1·NCT03441555·36 enrolled

Chronic Lymphocytic Leukemia5 trials

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00058240·52 enrolled

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003620·37 enrolled

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00098371·64 enrolled

Show 2 more trials

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00377104·24 enrolled

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Completed· Sanofi logo

Sanofi·Phase 2·NCT00464633·165 enrolled

Mantle Cell Lymphoma3 trials

Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003039·40 enrolled

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00058227·37 enrolled

Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00005074·33 enrolled

Pancreatic Cancer2 trials

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00047307·46 enrolled

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00331682·10 enrolled

27 more indications

Acute Leukemia2 trials

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00470197·35 enrolled

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00016016·53 enrolled

Multiple Myeloma2 trials

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00112723·46 enrolled

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00047203·35 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00042874·77 enrolled

Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00112684·25 enrolled

Breast Cancer2 trials

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00020332

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00039455·50 enrolled

Soft Tissue Sarcoma1 trial

Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00005974·18 enrolled

Refractory Cancer1 trial

Flavopiridol in Treating Patients With Refractory Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019344

Advanced Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00021073·90 enrolled

Lymphoma1 trial

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00012181·30 enrolled

Metastatic Solid Tumors1 trial

Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079352·24 enrolled

Melanoma1 trial

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00005971·17 enrolled

Liver Cancer1 trial

Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00087282

Primary Peritoneal Cancer1 trial

Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00083122·45 enrolled

Chronic Myelogenous Leukemia1 trial

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00278330·24 enrolled

Recurrent Sarcoma1 trial

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00098579·36 enrolled

Patients With Solid Tumors1 trial

Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00072436·58 enrolled

Metastatic Head and Neck Cancer1 trial

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020189

Endometrial Cancer1 trial

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00023894

Refractory or Recurrent Solid Tumor1 trial

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003004·73 enrolled

Prostate Cancer1 trial

Flavopiridol in Treating Patients With Recurrent Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003256·40 enrolled

Biomarker1 trial

Alvocidib Biomarker-driven Phase 2 AML Study

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 2·NCT02520011·104 enrolled

Acute Lymphoblastic Leukemia1 trial

Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00101231·88 enrolled

Hematologic Malignancies1 trial

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00070239·100 enrolled

Relapsed/Refractory AML1 trial

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 2·NCT03969420·11 enrolled

Hematologic Cancer1 trial

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT00064285·22 enrolled

Esophageal Cancer1 trial

Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00006245

Gastroesophageal Junction Cancer1 trial

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00991952·19 enrolled

Kidney Cancer1 trial

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00016939

Sources

References

[1]
ClinicalTrials.gov — 56 trial records for alvocidib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alvocidib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alvocidib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cyclin-Dependent Kinase 4 Inhibitor; Cyclin-Dependent Kinase 7 Inhibitor; Cyclin-Dependent Kinase 9 Inhibitor; Cyclin-Dependent Kinase 1 Inhibitor; Cyclin-Dependent Kinase 2 Inhibitor; Cyclin-Dependent Kinase 6 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sumitomo Pharma America, Inc.

Flavopiridol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patients With Advanced Solid Tumors8 trials

Acute Myeloid Leukemia7 trials

Chronic Lymphocytic Leukemia5 trials

Mantle Cell Lymphoma3 trials

Pancreatic Cancer2 trials

Acute Leukemia2 trials

Multiple Myeloma2 trials

Locally Advanced or Metastatic Solid Tumors2 trials

Breast Cancer2 trials

Soft Tissue Sarcoma1 trial

Refractory Cancer1 trial

Advanced Cancer1 trial

Lymphoma1 trial

Metastatic Solid Tumors1 trial

Melanoma1 trial

Liver Cancer1 trial

Primary Peritoneal Cancer1 trial

Chronic Myelogenous Leukemia1 trial

Recurrent Sarcoma1 trial

Patients With Solid Tumors1 trial

Metastatic Head and Neck Cancer1 trial

Endometrial Cancer1 trial

Refractory or Recurrent Solid Tumor1 trial

Prostate Cancer1 trial

Biomarker1 trial

Acute Lymphoblastic Leukemia1 trial

Hematologic Malignancies1 trial

Relapsed/Refractory AML1 trial

Hematologic Cancer1 trial

Esophageal Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News